NAVEEN PEMMARAJU to Risk
This is a "connection" page, showing publications NAVEEN PEMMARAJU has written about Risk.
Connection Strength
0.240
-
From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. Am Soc Clin Oncol Educ Book. 2015; 139-45.
Score: 0.090
-
Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs). Hematology Am Soc Hematol Educ Program. 2015; 2015:649-51.
Score: 0.090
-
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.
Score: 0.034
-
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
Score: 0.027